Latest filing published 05 Jun 2023 for TCR2 THERAPEUTICS INC.. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
UBS Oncology Impact Fund L.P. has filed trades across 2 companies (mainly through SEC (Form 4)), most often in Cullinan Therapeutics, Inc. and TCR2 Therapeutics Inc. Over a trading history stretching from 11 August 2021 to 1 June 2023, the count stands at 9 filings.
The open-market record consists of 8 sales worth €2.7M, with no purchase.
Most recently, on 5 June 2023, the filings show a transaction in TCR2 Therapeutics Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
9 of 9 declarations